Evidence map›Paper›PMID 38907774›Full record

ArticleVirchows Archiv : an international journal of pathology2024

PIT-EASY survey: validation of the European Pituitary Pathology Group proposal for reporting pituitary neuroendocrine tumors.

Maria Francesca Birtolo, Anne Jouinot, Alexandre Vasiljevic, Camille Boulagnon-Rombi, Sofia Asioli, Ghizelaine Bousdira, Louise Marie Mboua Tetka, Romain Perbet, Claude-Alain Maurage, Romain Appay and 9 more

Abstract readValidation StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Grading and staging for pituitary neuroendocrine tumors.Brain pathology (Zurich, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Maria Francesca Birtolo *Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.
Anne Jouinot *Université Paris Cité, CNRS, INSERM, Institut Cochin, F-75014, Paris, France.
Alexandre VasiljevicInserm U1052, CNRS UMR5286, Cancer Research Center of Lyon, 69373, Lyon, France.
Camille Boulagnon-RombiService de Pathologie, CHU de Reims, 51092, Reims, France.
Sofia AsioliDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Ghizelaine BousdiraService de Pathologie, CHU de Reims, 51092, Reims, France.
Louise Marie Mboua TetkaService de Pathologie, CHU de Reims, 51092, Reims, France.
Romain PerbetInstitute of Pathology, Centre de Biologie Pathologie, Lille University Hospital, Lille, France.
Claude-Alain MaurageInstitute of Pathology, Centre de Biologie Pathologie, Lille University Hospital, Lille, France.
Romain AppayAix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
Dominique Figarella-BrangerAix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
Guillaume GauchotteDepartment of Biopathology, CHRU-ICL, INSERM U1256 NGERE, Université de Lorraine, Vandoeuvre-Lès-Nancy, France.
Nathalie SturmDepartment of Anatomo-Cytopathology, Grenoble University Hospital, 38700, La Tronche, France.
Bertrand BaussartUniversité Paris Cité, CNRS, INSERM, Institut Cochin, F-75014, Paris, France.
Federico RoncaroliGeoffrey Jefferson Brain Research Centre, Division of Neuroscience, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Jérôme BertheratUniversité Paris Cité, CNRS, INSERM, Institut Cochin, F-75014, Paris, France.
Thierry BrueAix Marseille Univ, AP-HM, Inserm, MMG, MarMaRa, Marseille, France.
Chiara VillaUniversité Paris Cité, CNRS, INSERM, Institut Cochin, F-75014, Paris, France. chiara.villa@inserm.fr.ORCID http://orcid.org/0000-0001-6245-4487
CRMR HYPO, FIRENDO (French National Healthcare Network for Rare Endocrine Diseases)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this multicenter prospective survey called PIT-EASY was to assess the relevance of the European Pituitary Pathology Group (EPPG) diagnostic tools for pituitary neuroendocrine tumors (PitNETs) to improve the quality of their histological diagnosis. Each center performed at least 30 histological cases of PitNETs using the EPPG tools and assessed their value using a scorecard with 10 questions. For each center, the histological cases were carried out by pathologists with varying levels of expertise in pituitary pathology defined as junior, intermediate, and expert. Two hundred and ninety histological cases were collected from six French and Italian centers. The three EPPG tools were validated and regarded as helpful for a more accurate and time-efficient diagnosis. The usefulness of level 2 and level 3 of the "EPPG's multi-step approach for immunohistochemistry" including pituitary transcription factors (PIT1, TPIT, and SF1) and chromogranin, SSTRs, and P53 respectively was higher in "other non-functioning" (silent plurihormonal PIT1, silent corticotroph, and null cell): 88% vs 32%, p < 10-6 and 42% vs 14%, p = 0.002, respectively. The diagnostic algorithm proved more useful for junior pathologists (p = 0.0001) and those with intermediate experience. PIT-EASY survey confirmed the importance of a standardized approach to PitNETs for an accurate and reproducible diagnosis and served as validation of the EPPG proposal. The tool appeared to be of practical value to junior participants and staff with intermediate experience for safe routine diagnostic reporting.

Indexed as

Neuroendocrine TumorsPituitary NeoplasmsAdultBiomarkers, TumorEuropeFemaleHumansImmunohistochemistryMaleMiddle AgedProspective StudiesReproducibility of ResultsSurveys and QuestionnairesBiomarkers, TumorImmunostainingPitNETsPituitaryStandardized approach

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.